Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with >5 years of follow-up in patients with advanced renal cell carcinoma (aRCC) Meeting Abstract
| Authors: | Motzer, R. J.; Tykodi, S. S.; Escudier, B.; Oudard, S.; Hammers, H. J.; McDermott, D. F.; George, S.; Castellano, D.; Choueiri, T. K.; Alva, A. S.; Richardet, M. E.; Plimack, E. R.; Srinivas, S.; Procopio, G.; Donskov, F.; Gurney, H.; Tomita, Y.; McHenry, M. B.; Saggi, S. S.; Tannir, N. M. |
| Abstract Title: | Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with >5 years of follow-up in patients with advanced renal cell carcinoma (aRCC) |
| Meeting Title: | 2020 Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 38 |
| Issue: | 6 Suppl. |
| Meeting Dates: | 2020 Feb 13-15 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2020-02-20 |
| Language: | English |
| ACCESSION: | WOS:000529525900620 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2020.38.6_suppl.617 |
| Notes: | Meeting Abstract: 617 -- Source: Wos |
